Compendial Globalization: Achieving Harmonization through Standardized Practices and Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compendial Globalization: Achieving Harmonization through Standardized Practices and Collaboration
The authors discuss a new approach to address globally harmonized compendial standards.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 94-101

Twenty-first century challenges require 21st century solutions. This fact applies broadly in our current global economy, where many industries are looking beyond traditional, developed markets to the emerging markets. One such industry is healthcare, where medicines are used to extend and improve the quality of life for patients around the world. There is an increased need for consistent and appropriate quality requirements for medicines because disharmonized standards do not provide additional value or benefit, but rather increase the cost and complexity of bringing medicines to patients worldwide. Medicines may be globally sourced across developed and emerging markets, and the supply chain for ingredients and drug products is complicated by the overall lack of consistent, harmonized quality requirements.

The lack of harmonized drug standards is the result of several existing conditions, including national and regional laws, regulatory requirements and expectations, and applicable pharmacopeial (or compendial) requirements. Pharmacopeias with differing standards exist in many of the developed and emerging economies. The purpose of this paper is to initiate discussion on a new approach to address the challenge of achieving globally harmonized compendial standards for pharmaceutical ingredients and dosage forms. The concepts include development of standardized practices and enhanced collaboration among the pharmacopeias, as well as participation and agreement by the regulatory agencies.

Background

One approach to achieving harmonized quality requirements for medicines is the creation of a single, global compendial standard. This was a key consideration in the recently published article describing the "ideal pharmacopeia" (1). But this idea is not new. The original objective in the creation of the International Pharmacopoeia (Ph. Int.) more than 60 years ago under the direction of the World Health Organization (WHO) was the creation of a unified pharmacopeia. The European Pharmacopoeia (Ph. Eur.), first elaborated in 1964, is a more recent example of the successful creation of a single, harmonized, broadly applicable pharmacopeia, where several individual national pharmacopeias previously existed. It is also recognized that the United States Pharmacopeia–National Formulary (USP–NF) and the British Pharmacopoeia (BP) provide compendial standards that are applied well beyond their geographical boundaries.

Other approaches to developing harmonized compendial standards include the efforts by the Pharmacopeial Discussion Group (PDG) and International Conference on Harmonization's (ICH) Q4B guideline (2). These activities, which generally focus on retrospective harmonization of widely used general chapters and excipient monographs in the USP–NF, Ph. Eur., and Japanese Pharmacopoeia (JP), have achieved some success, but are limited in scope and are time-consuming. It is well understood that there are inherent challenges in retrospective harmonization. More recent approaches include the prospective harmonization pilot project, a collaboration between the pharmaceutical industry, Ph. Eur., and USP to achieve harmonized API monographs (3).

Although these approaches have provided some progress toward creating harmonized compendial standards, they have largely been limited in their breadth and depth. In consideration of today's continuing reality of multiple national and regional pharmacopeias, and our need to serve a global patient population, other approaches must be considered to achieve a 21st century solution.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here